TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
Maire V, Baldeyron C, Richardson M, Tesson B, Vincent-Salomon A, Gravier E, Marty-Prouvost B, De Koning L, Rigaill G, Dumont A, Gentien D, Barillot E, Roman-Roman S, Depil S, Cruzalegui F, Pierré A, Tucker GC, Dubois T.
Maire V, et al. Among authors: gravier e.
PLoS One. 2013 May 20;8(5):e63712. doi: 10.1371/journal.pone.0063712. Print 2013.
PLoS One. 2013.
PMID: 23700430
Free PMC article.